TMS-evoked potentials unveil occipital network involvement in patients diagnosed with Parkinson's disease within 5 years of inclusion

被引:1
|
作者
Zifman, Noa [1 ]
Levy-Lamdan, Ofri [1 ]
Hiller, Tal [1 ]
Thaler, Avner [2 ,3 ,4 ]
Dolev, Iftach [1 ]
Mirelman, Anat [2 ,3 ,4 ]
Fogel, Hilla [1 ]
Hallett, Mark [1 ,5 ]
Maidan, Inbal [2 ,3 ,4 ]
机构
[1] QuantalX Neurosci Ltd, Kefar Sava, Israel
[2] Tel Aviv Sourasky Med Ctr, Neurol Inst, Lab Early Markers Neurodegenerat LEMON, Tel Aviv, Israel
[3] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv, Israel
[4] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel
[5] NINDS, NIH, Bethesda, MD USA
关键词
DEMENTIA; SUBTYPES; SCALE; MOCA;
D O I
10.1038/s41531-024-00793-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Distinguishing Parkinson's disease (PD) subgroups may be achieved by observing network responses to external stimuli. We compared TMS-evoked potential (TEP) measures from stimulation of bilateral motor cortex (M1), dorsolateral prefrontal cortex (DLPFC), and visual cortex (V1) between 62 PD patients (age: 69.9 +/- 7.5) and 76 healthy controls (age: 69.2 +/- 4.3) using a TMS-EEG protocol. TEP measures were analyzed using two-way ANCOVA adjusted for MOCA. PD patients were divided into tremor dominant (TD), non-tremor dominant (NTD) and rapid disease progression (RDP) subgroups. PD patients showed lower wide-waveform adherence (wWFA) (p = 0.025) and interhemispheric connectivity (IHCCONN) (p < 0.001) compared to healthy controls. Lower occipital IHCCONN correlated with advanced disease stage (r = -0.37, p = 0.0039). The RDP and NTD groups showed lower wWFA in response to occipital stimulation than the TD group (p = 0.005). Occipital TEP measures identified RDP patients with 85% accuracy. These findings demonstrate occipital network involvement in early PD stages, suggesting that TEP measures offer insights into altered networks in PD subgroups.
引用
收藏
页数:9
相关论文
共 41 条
  • [31] RESTING-STATE NETWORK CONNECTIVITY IN NEWLY DIAGNOSED DRUG-NAIVE PARKINSON'S DISEASE PATIENTS WITH MILD COGNITIVE IMPAIRMENT
    Hou, Y.
    Wei, Q.
    Ou, R.
    Yang, J.
    Shang, H.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E11 - E11
  • [32] Dopamine transporter in 150 patients with Parkinson's disease and disease duration longer than 5 years: A DaTSCAN/SPECT imaging study
    Antonini, A
    De Notaris, R
    Benti, R
    Tesei, S
    Canesi, M
    Pezzoli, G
    MOVEMENT DISORDERS, 2004, 19 : S259 - S259
  • [33] Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients
    Leocadi, Michela
    Canu, Elisa
    Donzuso, Giulia
    Stojkovic, Tanja
    Basaia, Silvia
    Kresojevic, Nikola
    Stankovic, Iva
    Sarasso, Elisabetta
    Piramide, Noemi
    Tomic, Aleksandra
    Markovic, Vladana
    Petrovic, Igor
    Stefanova, Elka
    Kostic, Vladimir S.
    Filippi, Massimo
    Agosta, Federica
    JOURNAL OF NEUROLOGY, 2022, 269 (03) : 1485 - 1500
  • [34] Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson’s disease patients
    Michela Leocadi
    Elisa Canu
    Giulia Donzuso
    Tanja Stojkovic
    Silvia Basaia
    Nikola Kresojević
    Iva Stankovic
    Elisabetta Sarasso
    Noemi Piramide
    Aleksandra Tomic
    Vladana Markovic
    Igor Petrovic
    Elka Stefanova
    Vladimir S. Kostic
    Massimo Filippi
    Federica Agosta
    Journal of Neurology, 2022, 269 : 1485 - 1500
  • [35] The use of dopamine agonists (DAGs) in "de novo" Parkinson's disease patients (PDpts) first diagnosed after 70years old
    Rabey, J. M.
    Dubronevsky, E.
    Miniovich, A.
    Prokhovic, T.
    MOVEMENT DISORDERS, 2009, 24 : S226 - S226
  • [36] Different resting-state network disruptions in newly diagnosed drug-naive Parkinson's disease patients with mild cognitive impairment
    Hou, Yanbing
    Wei, Qianqian
    Ou, Ruwei
    Zhang, Lingyu
    Yuan, Xiaoqin
    Gong, Qiyong
    Shang, Huifang
    BMC NEUROLOGY, 2021, 21 (01)
  • [37] Levodopa fractionation in Parkinson's disease: half of the patients use more than four daily doses after 5 years
    Nyholm, D.
    Stepien, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 24 - 24
  • [38] Different resting-state network disruptions in newly diagnosed drug-naïve Parkinson’s disease patients with mild cognitive impairment
    Yanbing Hou
    Qianqian Wei
    Ruwei Ou
    Lingyu Zhang
    Xiaoqin Yuan
    Qiyong Gong
    Huifang Shang
    BMC Neurology, 21
  • [39] Which Parkinson's disease (PD) patients function well without levo-dopa (LDopa) treatment for more than 5 years?
    Au-Yeung, M.
    Tsoi, T. H.
    Cheung, C. M.
    Hou, S.
    Lee, C. N.
    Li, R.
    Yeung, E.
    MOVEMENT DISORDERS, 2009, 24 : S255 - S256
  • [40] Predictors for early-onset psychotic symptoms in patients newly diagnosed with Parkinson's disease without psychosis at baseline: A 5-year cohort study
    Chen, Jing
    Chen, Baoyu
    Zhao, Danhua
    Feng, Xiaotong
    Wang, Qi
    Li, Yuan
    Chen, Junyi
    Bai, Chaobo
    Guo, Xintong
    He, Xiaoyu
    Zhang, Lin
    Yuan, Junliang
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (03)